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Abstract
Aims/hypothesis Pancreatic beta cells secrete insulin to maintain glucose homeostasis, and beta cell failure is a hallmark of type 2
diabetes. Glucose triggers insulin secretion in beta cells via oxidative mitochondrial pathways. However, it also feeds mitochondrial
anaplerotic pathways, driving citrate export and cytosolic malonyl-CoA production by the acetyl-CoA carboxylase 1 (ACC1)
enzyme. This pathway has been proposed as an alternative glucose-sensing mechanism, supported mainly by in vitro data. Here,
we sought to address the role of the beta cell ACC1-coupled pathway in insulin secretion and glucose homeostasis in vivo.
Methods Acaca, encoding ACC1 (the principal ACC isoform in islets), was deleted in beta cells of mice using the Cre/loxP
system. Acaca floxed mice were crossed with Ins2cre mice (βACC1KO; life-long beta cell gene deletion) or Pdx1creER mice
(tmx-βACC1KO; inducible gene deletion in adult beta cells). Beta cell function was assessed using in vivometabolic physiology
and ex vivo islet experiments. Beta cell mass was analysed using histological techniques.
Results βACC1KO and tmx-βACC1KO mice were glucose intolerant and had defective insulin secretion in vivo. Isolated islet
studies identified impaired insulin secretion from beta cells, independent of changes in the abundance of neutral lipids previously
implicated as amplification signals. Pancreatic morphometry unexpectedly revealed reduced beta cell size in βACC1KO mice
but not in tmx-βACC1KO mice, with decreased levels of proteins involved in the mechanistic target of rapamycin kinase
(mTOR)-dependent protein translation pathway underpinning this effect.
Conclusions/interpretation Our study demonstrates that the beta cell ACC1-coupled pathway is critical for insulin secretion
in vivo and ex vivo and that it is indispensable for glucose homeostasis. We further reveal a role for ACC1 in controlling beta cell
growth prior to adulthood.
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Introduction
Beta cells adapt to metabolic challenges by increasing insulin
secretory output to maintain glycaemic control. This occurs
not only acutely in response to elevations in blood glucose but
also over the longer term during obesity and pregnancy, via an
expansion of beta cell mass and an enhancement of secretory
function. Conversely, failure of beta cell output to match de-
mand results in hyperglycaemia and progression towards type
2 diabetes. Delineating the mechanisms that maintain a func-
tional beta cell mass is therefore a key goal for diabetes re-
search. Surprisingly, there are still gaps in our understanding
of acute stimulus–secretion coupling, longer term adaptations
and the inter-relationships between these two processes,
which are often studied independently.
Glucose stimulates insulin secretion by sequentially in-
creasing glucose oxidation, ATP production, KATP channel
closure and calcium influx [1]. Acting in concert with this
triggering pathway, other glucose-regulated pathways en-
hance insulin secretion [2]. The factors underlying these amp-
lification pathways remain poorly understood [3], although
lipid metabolites may play a role [4]. Beta cells are dependent
on glucose oxidation to trigger insulin secretion, although on-
ly ~60% of glucose enters mitochondria via pyruvate
dehydrogenase (driving oxidation); the remaining ~40% of
glucose-derived pyruvate enters mitochondria via pyruvate
carboxylase [5], supporting an unexpectedly high rate of
glucose-driven anaplerotic flux and cellular citrate accumula-
tion [6], which closely tracks the insulin secretory response
[7]. This leads to the concept of an alternative glucose-sensing
mechanism utilising this anaplerotic flux.
Acetyl-CoA carboxylase (ACC) enzymes couple glucose
and lipid fluxes through anabolic and catabolic pathways.
ACC enzymes are allosterically activated by cytosolic citrate
[8] to catalyse malonyl-CoA synthesis from acetyl-CoA
(which can be derived from citrate). Malonyl-CoA is a sub-
strate of fatty acid synthase (FAS) and an inhibitor of
carnitine-palmitoyl transferase 1: therefore, ACC activity pro-
motes lipid production and repression of fat oxidation [9]. Of
the two ACC isoforms, ACC1 is expressed in lipogenic tis-
sues such as hepatocytes and adipocytes, whereas ACC2 is
expressed in oxidative tissues such as skeletal muscle [10]
where it is localised to the mitochondrial surface and regulates
β-oxidation [11]. Both malonyl-CoA and long-chain acyl-
CoAs, generated downstream of ACC, have been pro-
posed as metabolic coupling factors in beta cells
[12–14]. ACC1 but not ACC2 is expressed in human
[15] and rodent islets [15, 16].
In vitro evidence linking ACC1 to insulin secretion in beta
cells includes the stimulation of ACC activity in response to
glucose [17] and the impairment of glucose-stimulated insulin
secretion (GSIS) following pharmacological or genetic inhibi-
tion of ACC or depletion of malonyl-CoA [15, 16, 18, 19].
However, the role of ACC1 in beta cell function and adapta-
tion has not been examined in vivo and the physiological role
100 Diabetologia (2019) 62:99–111
of this pathway has yet to be determined. Global deletion of
the gene encoding ACC1 (Acaca) is embryonically lethal
[10]. Therefore, the aim of our present study was to generate
mice with the Acaca gene deleted specifically in beta cells,
using two temporally distinct genetic approaches, to assess
the role of beta cell ACC1 activity in insulin secretion and
glucose homeostasis in vivo.
Methods
For detailed methods, please refer to the electronic supple-
mentary material (ESM) Methods.
Mouse models To disrupt ACC1 activity in beta cells, Acaca
floxedmice [20, 21] were crossed with Ins2cre mice (Tg(Ins2-
cre)25Mgn) [22] to generate Ins2cre-Acaca f lox/f lox
(βACC1KO) and littermate control Ins2cre (INS2cre) mice.
To enable tamoxifen-inducible disruption of ACC1 activity in
beta cells, Acaca floxed mice were crossed with Pdx1creER
mice (Tg(Pdx1-cre/Esr1*)35.10Dam) [23]: experimental
mice received s. c. tamoxifen injections at 10 weeks of age
to generate tamoxifen-treated Acacaflox/flox, Pdx1-creER
(tmx-βACC1KO) and littermate control tamoxifen-treated
Acacaflox/flox (tmx-Control) mice, providing temporal resolu-
tion on the role of ACC1 in beta cell function. Mice were
maintained on a C57Bl/6 J background.
Metabolic testing Glucose tolerance tests were performed af-
ter a 16 h fast, by i. p. (2 g/kg) or i. v. (1 g/kg) injection of
glucose. Insulin action was assessed by i. p. injection of insulin
(0.75 U/kg) following a 6 h fast. Blood was sampled from the
tail. Percentage body fat was determined by dual energy x-ray
absorptiometry (DEXA) scan normalised to body weight.
Islet isolation, culture and insulin secretion assaysMouse islet
studies were performed as previously described [24]. The pan-
creas was perfused with collagenase solution via the common
bile duct, before excision, digestion at 37°C and mechanical
disruption. Islets were recovered using a Ficoll-Paque gradient
(GE Healthcare, Chalfont St Giles, UK) and cultured over-
night. To assess ex vivo insulin secretion, islets were pre-
incubated for 1 h in HEPES-buffered KRB (KRBH) contain-
ing 0.1% BSA and 2 mmol/l D-glucose, before batches of five
size-matched islets were incubated at 37°C for 1 h with glu-
cose, palmitate-BSA [25], KCl or diazoxide.
Hormone and DNA assays Insulin was quantified by ELISA
(Crystal Chem, Elk Grove Village, IL, USA) or RIA (Merck
Millipore, Burlington, MS, USA). Glucagon was quantified
by RIA (Merck Millipore). Total pancreatic hormone content
was quantified following homogenisation in ice-cold acid–
ethanol. Batches of islets were lysed and DNA content
quantified by SYBR green assay (ThermoFisher, Waltham,
MA, USA) using salmon-sperm DNA standards [25].
Islet metabolic studies Glucose tracer measurements were
performed as described [26]. Batches of 100 islets were
cultured for 2 h at 37°C in KRBH containing 0.1% BSA
and 2.8 or 20 mmol/l D-glucose with 0.5 × 106 or 0.07 × 106
MBq/mol D-[U-14C]glucose, respectively; (Perkin Elmer,
Waltham, MA, USA). To quantify tracer oxidation, media
was acidified and 14CO2 trapped via reaction with 0.1 ml
KOH before liquid scintillation spectrometry. To quantify
tracer incorporation into cellular lipids, a chloroform–
methanol (2:1 vol./vol.) extraction was performed and
fractions assayed by scintillation spectrometry.
MS based lipidomic analysis of islets was performed as de-
scribed [27]. Lipids were extracted from 100 islets per mouse
using chloroform–methanol (2:1) with a panel of internal lipid
standards. Analysis was performed by electrospray ionisation–
tandem MS using an API 4000 Q/TRAP mass spectrometer
(Sciex, Framingham, MA, USA) with a turbo-ionspray source
and Analyst 1.5 data system, following prior liquid chromato-
graphic separation. Quantification of individual lipid species was
performed using scheduled multiple-reaction monitoring in pos-
itive ion mode. Lipid concentrations were calculated by relating
the peak area of each species to the peak area of the correspond-
ing internal standard.
Histology Formalin-fixed paraffin-embedded pancreases were
sectioned and immunostained using the primary antibodies indi-
cated. For morphometry, stained sections were imaged with an
Arperio slide scanner (Leica Biosystems, Wetzlar, Germany),
and analysis performed using Imagescope software (Leica
Biosystems): beta cell mass was calculated as described [28]
using data averaged from three pancreatic sections per mouse.
For dual immunofluorescent staining, sections were imaged
using aDMI6000 SP8Confocalmicroscope (Leica Biosystems).
Western blotting Tissue and cells were lysed in radioimmuno-
assay precipitation (RIPA) buffer and western blotting performed
as previously described [24] using the primary antibodies indi-
cated. Band density was quantified using Image J software (NIH,
Bethesda, MA, USA). ACC1 protein was identified by avidin–
agarose bead pull-down, SDS-PAGE, transfer to polyvinylidene
difluoride (PVDF), incubation with streptavidin–horseradish per-
oxidase (HRP) (ThermoFisher) and chemiluminescent detection:
this method utilises the affinity of the endogenous ACC1-bound
biotin for avidin/streptavidin and has been described previously
[20].
Statistics Data are presented as mean ± SEM. Simple pairwise
comparisons were made using two-tailed t tests (unpaired unless
otherwise stated). Multiple comparisons were made using two-
way ANOVA with Bonferroni post-tests. A p value <0.05 was
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regarded as statistically significant. Statistics were performed
using Prism6 (Graphpad Software, San Diego, CA, USA).
Results
Loss of ACC1 in Ins2-expressing tissues blocks glucose-driven
de novo lipogenesis in beta cells To test the role of the ACC1-
coupled pathway in beta cells we generated mice with beta
cell Acaca deletion (βACC1KO) in Ins2-expressing tissues.
PCR of genomic DNA revealed recombination of loxP sites
only in the islets, hypothalamus and brain of βACC1KO
mice, and not in the other tissues tested; recombination could
not be detected in any of the tissues tested in Acaca floxed
mice in the absence of Cre-recombinase (Fig. 1a). ACC1 pro-
tein levels were reduced by 70% in βACC1KO mouse islets
(Fig. 1b), consistent with the >95% beta cell gene deletion
efficiency reported for the INS2cre mouse [29] and the 75%
beta cell content of mouse islets [30]. ACC1 function was
ablated in βACC1KO mouse islets, as determined by the im-
paired flux of D-[U-14C]glucose tracer into total lipid pools
(Fig. 1c). In contrast, flux into aqueous metabolites (Fig. 1d)
and glucose oxidation (Fig. 1e) were unaltered. The residual
ACC1-insensitive flux of D-[U-14C]glucose into βACC1KO
mouse islet lipids may reflect de novo lipogenesis in alpha
cells and/or incorporation of glycerol-3-phosphate, derived
from glycolysis, into glycerolipids [31].
Pre-labelling of islets with [U-14C]palmitate revealed that
incorporation of exogenous fatty acids into beta cell lipid pools
or aqueous metabolites is not affected by loss of ACC1 (ESM
Fig. 1a,b). Moreover, the rate of β-oxidation was very low in
islets relative to glucose oxidation andwas not altered byACC1
loss (ESM Fig. 1c), consistent with ACC1 (the principal ACC
isoform in islets [15, 16]) catalysingmalonyl-CoA synthesis for
lipogenesis rather than inhibition of β-oxidation.
To assess how these alterations in flux might impact on
lipid mass, we undertook mass spectroscopic lipidomics.
This revealed that loss of ACC1 did not alter the abundance
of major neutral lipid species of diacylglycerol (DAG) and
triacylglycerol (TAG) (ESM Fig. 1d,e), including key
glucose-sensitive species [32]. In contrast, some forms of
phospholipid, especially high-abundance species such as
34:1 phosphatidylcholine and 38:4 phosphatidylinositol, were
significantly diminished (ESM Fig. 1f–i). This suggests that
ACC1-driven de novo fatty acid synthesis plays little role in
maintaining neutral lipid pools in the beta cell but makes a
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Fig. 1 Deletion of Acaca in beta cells impairs glucose-driven lipogenesis
in mice. (a) PCR analysis to confirm deletion of the floxed Acaca allele
(indicated by arrow) in Ins2cre-Acacaflox/flox (βACC1KO) but not in
Acacaflox/flox (ACC1 flox) mice. A control PCR confirmed amplifiable
DNA template in all samples (upper band). (b) ACC1 protein in islet
lysates assessed by avidin pull-down and streptavidin–HRP detection.
Pyruvate carboxylase (PC) was used as a loading control. n=3 batches
of islets from independent mice. (c–e) A D-[U-14C]glucose tracer was
used to measure glucose-drivenmetabolic flux in islets isolated frommice
and incorporation into cellular lipid pools (c), aqueous metabolites (d)
and glucose oxidation (e) were quantified. White bars, INS2cre mouse
islets; grey bars, βACC1KO mouse islets. n=4 batches of islets from
independent mice. Data are presented as mean ± SEM. *p<0.05,
**p<0.01 and ***p<0.001 (unpaired two-tailed t test). Quad, quadriceps;
WAT, white adipose tissue
102 Diabetologia (2019) 62:99–111
small but significant contribution to the abundance of some
major phospholipids.
Loss of ACC1 in Ins2-expressing tissues impairs insulin secre-
tion and glucose homeostasis in vivo To investigate the role of
ACC1 in beta cell function in vivo, we assessed glucose
homeostasis in βACC1KO mice at 12 weeks of age (young
adult). Intraperitoneal glucose tolerance tests (IPGTTs) re-
vealed significantly elevated blood glucose levels in
βACC1KO mice, relative to INS2cre control mice (Fig. 2a).
In the fed and (16 h) fasted state, βACC1KO mice displayed
significant elevations of blood glucose and corresponding de-
creases in circulating insulin (Fig. 2b–e): these data suggest
that insufficient insulin secretion underlies the glucose-
intolerant phenotype. This was further supported by an
IVGTT, which confirmed glucose intolerance (Fig. 2f), along
with a reduction in basal and GSIS (Fig. 2g). This clearly
demonstrates that ACC1 controls insulin secretion in vivo.
Loss of ACC1 in Ins2-expressing tissues does not alter adipos-
ity or insulin action The INS2cre mouse line can promote gene
deletion in neuronal populations [33], with associated
metabolic phenotypes such as weight gain and hyperphagia
[34]. Moreover, it has been reported that deletion of the gene
encoding FAS, using the INS2cre mouse, results in changes in
energy balance due to alterations in central peroxisome
proliferator-activated receptor α (PPARα) signalling [35]. We
therefore addressed neuronal metabolic signalling. Relative to
INS2cre control mice, our βACC1KO mice showed a small
but significant decrease in bodyweight at 12 weeks of age (Fig.
3a). This decrease was less pronounced than that reported for
FAS deletion in INS2cre neurones [35]. However, we found no
difference in proportional body fat (Fig. 3b) or insulin action
(Fig. 3c) between the βACC1KO and INS2cre mice at
12 weeks of age, indicating that regulation of adiposity and
insulin sensitivity is not affected by loss of ACC1 activity in
INS2cre-expressing tissues. The small reduction in body
weight in 12-week-old βACC1KO mice is unlikely to explain
the impairment in glucose tolerance we observe because by
12 months of age βACC1KO mice had regained a normal
body weight (Fig. 3d) yet remained profoundly glucose intol-
erant (Fig. 3e,f). Furthermore, 12-week-old femaleβACC1KO
mice exhibited normal body weight (Fig. 3g) while displaying
impaired glucose tolerance (Fig. 3h,i).
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ACC1 is necessary for normal insulin secretion ex vivo
Assessment of islet function ex vivo revealed that insulin se-
cretion was defective both at baseline and in response to glu-
cose stimulation in βACC1KO mouse islets (Fig. 4a). This is
consistent with previous reports that inhibition of the ACC1-
coupled pathway disrupts glucose-stimulated [15, 16, 19] and
basal [19] insulin secretion. Despite a marked reduction in the
quantity of insulin secreted, βACC1KO islets retained some
glucose responsiveness at 5.5 mmol/l glucose, relative to
2 mmol/l glucose (INS2cre 2.34-fold basal vs βACC1KO
1.28-fold basal), and this recovered further at higher glucose
concentrations.
We next considered whether the defective insulin secretion
in βACC1KO islets could be restored by provision of
exogenous NEFA, which modulate GSIS by both intracellular
and extracellular mechanisms [36]. Acute treatment of isolat-
ed islets with palmitate potentiated GSIS in both genotypes
(Fig. 4b), demonstrating that the response to NEFA stimula-
tion was intact. However, insulin release remained significant-
ly impaired in βACC1KO mouse islets at basal and physio-
logical glucose concentrations, in the presence of palmitate,
relative to control mouse islets (Fig. 4b). Thus, the secretory
defect in βACC1KO islets cannot be rescued with exogenous
fatty acids.
Production of malonyl-CoA and modulation of cellular lip-
id levels has been implicated in the amplifying pathways of
GSIS [4]. We therefore assessed these pathways using an
established pharmacological method: the KATP channel is
maintained open with diazoxide and the beta cell is artificially
depolarised with KCl to induce calcium influx [2]. Under
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these conditions, marked amplification of insulin secretion by
glucose was retained in both control and βACC1KO mouse
islets (Fig. 4c). Therefore, ACC1 is not required for a func-
tional amplifying pathway at high glucose concentrations.
Although loss of ACC1 activity inhibited insulin secretion
at baseline and in response to physiological concentrations of
glucose (Fig. 4a), no impairment was observed in response
either to supraphysiological concentrations of glucose
(20 mmol/l) or to KCl (Fig. 4c). This indicates that
βACC1KO mouse islets have functional insulin exocytosis
pathways but fail to respond to physiological glucose concen-
trations, suggesting a right shift in the GSIS curve. One
explanation for this could be a reduction in glucokinase levels
or mitochondria; however, levels of glucokinase and mito-
chondrial heat shock protein 9 (HSPA9) were unaltered in
βACC1KO mouse islets (ESM Fig. 2a).
ACC1 is required for beta cell growth Using histological mor-
phometric techniques, we next identified a significant 46%
reduction in beta cell mass in βACC1KO mice, relative to
INS2cre control mice (Fig. 5a), with a corresponding decrease
in pancreatic insulin content (Fig. 5b). In contrast, glucagon
content was not altered by genotype (Fig. 5c), arguing against
a major phenotype in alpha cells. Interestingly, the observed
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Fig. 5 ACC1 is necessary for an adequate beta cell mass. (a)
Morphometric analysis of immunostained pancreatic sections was per-
formed to quantify beta cell mass. (b, c) Insulin (b) and glucagon (c)
content of pancreases homogenised in acid–ethanol was determined by
radioimmunoassay. (d) Further morphometric analysis revealed a reduc-
tion in mean beta cell volume, which was calculated by dividing insulin-
positive area (containing at least 1000 cells) by the number of cells/nuclei
in that area. (e) Pancreatic sections were immunostained for Ki67 and
insulin to quantify beta cell proliferation rates. (f, g) Dual immunofluo-
rescent imaging of formalin-fixed paraffin-embedded pancreatic sections
for insulin (INS; red) and glucagon (GCG; green); scale bars, 50 μm.
White bars, INS2cre mouse pancreas; grey bars, βACC1KO mouse pan-
creas. Data are presented as mean ± SEM. Each data point represents an
individual mouse. *p<0.05, **p<0.01 and ***p<0.001 (unpaired two-
tailed t test)
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decrease in beta cell mass appears to be partly explained by a
31% reduction in individual beta cell size (Fig. 5d), whereas
both proliferation (Fig. 5e) and apoptosis (ESM Fig. 2b) rates
were unaltered. To evaluate this further we measured DNA
content as a surrogate of cell number, using equal numbers of
size-matched islets: those from βACC1KO mice showed an
18% increase in DNA content relative to those from INS2cre
mice (Table 1), indicating that these islets contain a greater
number of smaller beta cells. In contrast, mean islet insulin
content was not significantly altered in βACC1KO mice, ex-
cept when normalised for islet DNA content (effectively nor-
malising for cell number) (Table 1), reflecting reduced beta
cell size. Dual immunofluorescent staining for insulin and
glucagon in βACC1KO pancreatic sections showed normal
islet architecture with a clear alpha cell mantle surrounding a
beta cell core (Fig. 5f,g). These results reveal that ACC1 ac-
tivity is necessary for the regulation of individual beta cell size
and the overall mass of beta cells in the pancreas.
Short-term loss of beta cell ACC1 activity in adult mice im-
pairs glucose tolerance and insulin secretion in vivo As the
Ins2 promoter is first activated around embryonic day 11.5
[37], we cannot discriminate between the role of ACC1 in
beta cell development and its role in mature beta cell function
using our βACC1KO model. To assess the role of ACC1
specifically in beta cells in adult mice, we crossed Acaca
floxed mice with the tamoxifen-inducible Pdx1creER line
[23]. Young adult male mice with inducible beta cell Acaca
deletion (tmx-βACC1KO) were generated by injection of ta-
moxifen at 10 weeks of age; tamoxifen-treated Acaca floxed
mice were used as a control group (tmx-Control). Specific
deletion of the Acaca floxed allele was confirmed in islets
isolated from tmx-βACC1KO but not tmx-Control mice
(Fig. 6a). At 4 weeks post-tamoxifen administration (14 weeks
of age), IPGTTs revealed pronounced glucose intolerance
(Fig. 6b), accompanied by elevated fasted and fed blood glu-
cose levels (Fig. 6c,d), in tmx-βACC1KO mice. During an
IVGTT, tmx-βACC1KO mice showed glucose intolerance
(Fig. 6e) with defective insulin secretion at baseline and in
response to glucose stimulation (Fig. 6f–h). These data indi-
cate that defective insulin secretion and elevated blood glu-
cose levels due to loss of beta cell ACC1 activity are not due to
developmental effects.
We are unaware of any reports of Pdx1creER transgene ex-
pression in the brain; however, a non-induciblePdx1cremade by
the same laboratory [23] showed Cre-recombinase activity in the
hypothalamus and brainstem [33]. Notwithstanding this, we
could not detect recombination of the Acaca floxed allele by
PCR in the hypothalamus or brain of tmx-βACC1KO mice
(Fig. 6a), whereas recombination was readily detectable in these
tissues from βACC1KO mice (Fig. 1a). Furthermore,
tmx-βACC1KO mice showed no evidence of a neuronal or
insulin-resistant phenotype: body weight (Fig. 6i), adiposity
(Fig. 6j) and insulin action (Fig. 6k) were all unaltered relative
to control mice. Taken together, these data clearly indicate a beta
cell specific phenotype in tmx-βACC1KO mice.
Short-term loss of beta cell ACC1 activity in adult mice im-
pairs insulin secretion, but not beta cell massWe next isolated
Table 1 DNA and insulin content of βACC1KO and INS2cre mouse
islets
Genotype Islet DNA content
(ng)
Islet insulin content/DNA content
(ng/ng)
INS2cre 14.67 ± 0.67 4.32 ± 0.49
βACC1KO 17.3 ± 1.03* 2.63 ± 0.54*
Data are presented as mean ± SEM, n=10 mice per genotype
Batches of 100 size-matched isolated islets per mouse were collected,
lysed and DNA and insulin content quantified before normalising for islet
number
*p<0.05 for βACC1KO vs INS2cre (unpaired two-tailed t test)
Fig. 6 Short-term loss of beta cell ACC1 activity in adult mice causes
glucose intolerance and impaired insulin secretion. Male mice received 2
× daily 8mg tamoxifen s. c. injections at 10weeks of age to generate tmx-
βACC1KO and tmx-Control mice. (a) PCR analysis to confirm deletion
of the floxed Acaca allele (lower band; indicated by arrow) 1 week post
tamoxifen treatment in Pdx1creER-Acacaflox/flox (tmx-βACC1KO) mice
but not in Acacaflox/flox (tmx-Control) mice. A control PCR confirmed
amplifiable DNA template in all samples (upper band). (b) Blood glucose
levels and AUC during an IPGTT (16 h fast, 2 g/kg glucose dose) in male
tmx-βACC1KOmice (n=17) and controlmice (n=18) at 14weeks of age;
p=0.0002 for genotype effect across all time points (by two-way
ANOVA). (c, d) Blood glucose levels in 16 h fasted (c) and fed (d) 14-
week-old male mice (n=24 tmx-βACC1KO mice or 25 tmx-Control
mice). (e–h) IVGTT was carried out with 17-week-old male mice to
assess GSIS in vivo (16 h fast, 1 g/kg glucose dose). Blood glucose and
insulin levels (e, f, n=25 tmx-βACC1KO mice or 26 tmx-Control mice)
were determined; p=0.0002 and p=0.0014 for genotype effect on glucose
and insulin across all time points, respectively (two-way ANOVA).
Fasted (16 h) blood insulin (g) and 0–15 min insulin AUC (h) were
determined from the IVGTT data and presented as mean data from five
independent cohorts of mice. (i–k) Bodyweight (i, n=17 tmx-βACC1KO
mice and 18 tmx-Control mice), proportional body fat (j, n=6 tmx-
βACC1KO mice and 7 tmx-Control mice) and intraperitoneal insulin
action (6 h fast, 0.75 U/kg insulin i.p.) (k, n=17 tmx-βACC1KO mice
and 18 tmx-Control mice) weremeasuredwhenmice were aged 14weeks
(i, j) or 15 weeks (k). (l) Ex vivo insulin secretion was assayed using islets
isolated from 15-week-old mice (n=6 per genotype). (m) Beta cell mass
was quantified by morphometric analysis of immunostained pancreatic
sections (n=5 per genotype). (o, p) Dual immunofluorescent imaging of
formalin-fixed paraffin-embedded pancreatic sections from tmx-Control
(o) and tmx-βACC1KO (p) mice stained for insulin (INS; red) and
glucagon (GCG; green); scale bars, 50 μm. White bars and squares,
tmx-Control mice or islets; grey bars and black squares, tmx-
βACC1KO mice or islets. Data are presented as mean ± SEM.
*p<0.05, **p<0.01 and ***p<0.001 (two-way ANOVA with
Bonferroni multiple comparisons test for time plots, for tmx-
βACC1KO vs tmx-Control at time point shown; unpaired two-tailed t
tests for bar charts, except for g and h, which are paired by cohort). Quad,
quadriceps; WAT, white adipose tissue
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islets from tmx-βACC1KO mice at 6 weeks post-tamoxifen
injection and assessed insulin secretion profiles. Interestingly,
loss of ACC1 in this model impaired GSIS at 20 mmol/l glu-
cose (Fig. 6l). This is in contrast with βACC1KO mouse
islets, where secretion was defective at 2, 5.5 and 7.5 mmol/l
glucose but not at 20 mmol/l glucose. The tmx-βACC1KO
mouse islets did not show a significant difference in insulin
secretion either at basal glucose or in response to KCl stimu-
lation (Fig. 6l). Therefore, short-term loss of ACC1 activity in
adult beta cells (tmx-βACC1KO) results in a pronounced de-
fect in GSIS. In contrast, life-long loss of beta cell ACC1
activity (βACC1KO) results in defective insulin secretion at
baseline and in response to moderate physiological glucose
concentrations. Glucokinase and HSPA9 levels were
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unaltered in tmx-βACC1KO mouse islets, similar to
βACC1KO islets (ESM Fig. 2c).
Pancrea t i c morphomet ry conduc ted wi th the
tmx-βACC1KOmodel 6 weeks post-tamoxifen did not reveal
any significant change in beta cell mass (Fig. 6m).
Furthermore, DNA content from size-matched-islet prepara-
tions was not altered in tmx-βACC1KO mice relative to con-
trol mice (ng DNA/islet, mean ± SEM: tmx-Control 10.98 ±
0.65; tmx-βACC1KO 10.90 ± 0.99; n = 6 mice). Dual
immunofluorescent staining for insulin and glucagon showed
normal islet architecture in tmx-βACC1KO pancreatic sec-
tions (Fig. 6o,p). Taken together, these results suggest that
beta cell size and mass are not altered following short-term
loss of ACC1 activity in adult beta cells.
mTOR substrate levels are reduced in βACC1KO mouse islets
Our data reveal that long-term loss of ACC1 activity impairs
insulin secretion and beta cell mass. Mechanistic target of
rapamycin kinase (mTOR) is an anabolic serine/threonine
kinase that controls protein biosynthesis, cell growth and cell
proliferation [38]. Genetic activation of mTOR results in en-
hanced beta cell growth and increased insulin secretion in
mouse beta cells [39], whereas pharmacological inhibition of
mTOR dramatically inhibited insulin secretion and reduced
beta cell mass in a rodent model of obesity [40]. Because
mTOR is activated by de novo synthesis of phosphatidic acid
[41], we hypothesised that loss of mTOR activity may under-
lie the reduction in beta cell size observed in βACC1KO
islets. To investigate this, we performed western blotting for
the mTOR kinase substrates responsible for translational con-
trol: ribosomal protein S6 kinase, polypeptide 1 (P70S6K) and
eukaryotic translation initiation factor 4E binding protein 1
(4EBP1). Although there was a significant decrease in phos-
phorylation of these mTOR targets in βACC1KO mouse
islets, consistent with a reduction in mTOR activity, this was
accompanied by a proportional decrease in total protein levels
of P70S6K (Fig. 7a,b). This resulted in reduced phosphoryla-
tion of the P70S6K substrate ribosomal protein S6 (Fig. 7a,b).
In contrast, levels of these proteins/phosphoproteins were not
altered in tmx-βACC1KO mouse islets, 6 weeks post-
tamoxifen injection (Fig. 7c,d), consistent with the normal
beta cell mass in this short-term Acaca deletion model.
These data suggest that chronic loss of ACC1-coupled signal-
ling in beta cells results in reduced activity of translational
control proteins, which may underlie the reduced beta cell size
in the βACC1KO model.
Discussion
Our study demonstrates for the first time that ACC1 activity is
required to maintain a functional beta cell mass and glucose
homeostasis in vivo, thereby extending prior in vitro findings
[15–19]. Using both acute and chronic beta cell gene deletion
models, we show that the ACC1 pathway is necessary for
adequate insulin secretion in vivo.This work identifies a novel
role for the ACC1 pathway in regulating beta cell size that is
temporally distinct from its effects on beta cell function. The
ACC1 protein is present in human islets [15], indicating that
our results are relevant for understanding human beta cell
function.
Our study made use of two independent murine Cre lines,
enabling us to distinguish the life-long effects of loss of beta
cell ACC1 activity (βACC1KO mouse) from the adult-
specific effects (tmx-βACC1KO mouse). Both models dem-
onstrate that beta cell ACC1 plays a critical role in insulin
secretion in vivo and ex vivo. Interestingly, there was a pro-
nounced defect in GSIS at 20 mmol/l glucose in
tmx-βACC1KO mice, consistent with the impaired secretion
in response to glucose concentrations >16 mmol/l observed
using pharmacological ACC1 inhibition in vitro [15, 16, 18,
19]. In contrast, the secretory defect in βACC1KO mice was
only present at mid-physiological and basal glucose concen-
trations, suggestive of a degree of compensation to restore
insulin secretion at higher glucose concentrations following
long-term loss of beta cell ACC1. Furthermore, impairments
in basal insulin secretion are consistent with reports using
malonyl-CoA depleted INS(832/13) beta cells [19].
Although it is clear from our data and those of others that
ACC1 activity is required for normal insulin secretion, the
mechanism(s) underlying this effect have been unclear. One
early proposal envisaged malonyl-CoA as a metabolic switch
to inhibit fatty acid oxidation in beta cells, thereby acting to
modulate lipid signalling and amplify insulin secretion [4].
However, in other tissues this switching function largely de-
pends on ACC2 [11], which is not present in beta cells [15,
16]. Our data suggest that ACC1 cannot subsume this role,
and argue more generally against the metabolic switch hy-
pothesis. Indeed, we observed no disinhibition of palmitate
oxidation in the Acaca knockout model, nor did repletion of
cellular fatty acid pools with exogenous palmitate revert the
secretory defect. Likewise, the levels of key TAG and DAG
species previously implicated in glucose-stimulated lipid turn-
over [32] were unaltered by Acaca gene deletion. This does
not exclude the possibility that amplification factors might be
derived from TAG [4] but rather that ACC1 (via metabolic
switching and/or de novo fatty acid synthesis) does not con-
tribute to the maintenance of the TAG precursor pool. Indeed,
our results clearly decouple ACC1 from the GSIS amplifica-
tion pathways and highlight the need for alternative mecha-
nisms to explain the links between GSIS and de novo lipogen-
esis as exemplified here and in earlier studies using inhibition
of ACC1 and/or FAS [15]. For example, ACC1may influence
membrane fluidity and vesicle fusion: mice with loss of liver
kinase B1 (LKB1) in beta cells show disinhibition of ACC1,
increased cellular fatty acid levels and enhanced membrane
108 Diabetologia (2019) 62:99–111
excitability and insulin secretion [42]. The reduction of some
phospholipid species we observed with ACC1 loss might be
consistent with these possibilities but this would need to be
tested in future studies focusing on individual cellular
compartments.
In contrast to the marked secretory defect observed in both
our models, mice with deletion of the gene encoding FAS in
Ins2-expressing tissues exhibited normal insulin secretion
in vivo and ex vivo [35], suggesting that ACC1-mediated
malonyl-CoA production or acetyl-CoA consumption, rather
than subsequent FAS-mediated lipogenesis, may control beta
cell function. This concept is consistent with the 30-fold aug-
mentation of ACC activity in glucose-stimulated INS-1 cells,
compared with only a threefold increase in FAS activity [17].
Therefore, it is plausible that changes in malonyl-CoA, rather
than a product of downstream lipogenesis, directly couple the
ACC1 pathway with insulin secretion, such as by altering
protein malonylation [43].
Another possibility is that ACC1 controls insulin secretion
by regulating cellular acetyl-CoA availability. Acetyl-CoA is
a substrate of ACC1, and loss of ACC1/ACC2 activity in the
liver dysregulates protein acetylation [20]. Moreover, beta cell
acetyl-CoA is an important acute potentiator of insulin secre-
tion, likely acting by enhancing protein acetylation [44].
However, in beta cells with persistent loss of ACC1 activity,
as in our models, it is possible that chronically elevated acetyl-
CoA levels may incur a secretory defect, analogous to the
generation of glucotoxicity following long-term glucose ex-
posure. For example, altered acetylation of proteins in the
glycolytic pathway and tricarboxylic acid cycle, as in the
ACC-null liver [20], may impair metabolic coupling in
ACC1-null beta cells. Likewise, acetoacetate breakdown
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Fig. 7 Chronic loss of beta cell ACC1 activity results in reduced levels of
translational regulator proteins. Islets were isolated from 14-week-old
male βACC1KO and INS2cre mice (a, b, n=8 mice per group) and from
tmx-βACC1KO (n=9) and tmx-Control mice (n=8) 4 weeks post-tamox-
ifen injection (c, d). Western blotting analysis of islet lysates was per-
formed using antibodies against the indicated proteins/phosphoproteins
(a, c); quantification of band densities shows protein levels in each sam-
ple relative to the mean control signal (b, d). In (b), white bars, INS2cre
mouse islets; grey bars, βACC1KOmouse islets. In (d), white bars, tmx-
Control mouse islets; grey bars, tmx-βACC1KO mouse islets. Data are
presented asmean ± SEM. *p<0.05, **p<0.01 and ***p<0.001 (unpaired
two-tailed t test)
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provides acetyl-CoA to ACC1 in beta cells via a pathway
distinct from ATP citrate lyase [45]. It is therefore plausible
that loss of ACC1 activity could result in persistent elevations
of acetoacetate, contributing to defective beta cell function in
βACC1KO and tmx-βACC1KO mice.
Our study has revealed, somewhat unexpectedly, that beta
cell mass and individual beta cell size are reduced with lifelong
loss of ACC1 activity in beta cells. This suggests a novel role
for ACC1 in regulating beta cell growth during the marked
expansion of beta cell mass that occurs during adolescence
[28]. In contrast, beta cell mass was not significantly altered
in tmx-βACC1KO mice 6 weeks post ACC1 deletion: this is
perhaps not surprising, given that relatively little beta cell ex-
pansion is expected to occur during this adult period. Therefore,
our results are consistent with ACC1 playing a role in the ex-
pansion, rather than the maintenance, of beta cell mass.
Consistent with our beta cell mass data, we observed de-
creased abundance of key translational/growth regulators in
βACC1KO mice but not in tmx-βACC1KO mice.
Interestingly, acetylation of P70S6K inhibits its kinase activity
[46], suggesting a potential link between ACC1 activity,
acetyl-CoA availability and the regulation of protein transla-
tion. Although total P70S6K levels decreased in proportion to
the decrease in S6 phosphorylation in βACC1KO islets, a
reduction in P70S6K activity associated with increased
acetyl-CoA levels cannot be ruled out.
In summary, our study reveals a critical role for ACC1
activity in controlling insulin secretion and beta cell mass
in vivo through mechanisms independent of neutral lipid
abundance. We further propose that ACC1 activity is a posi-
tive regulator of protein synthesis and beta cell growth.
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